[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors",
    "summary": "In the most recent trading session, AbbVie (ABBV) closed at $171.63, indicating a -1% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=0559089892f0445edf2ede60b40d3f0dfbe4cce9e6181ef1753fdd64d2e3ff11",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734389116,
      "headline": "AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors",
      "id": 132018675,
      "image": "https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "In the most recent trading session, AbbVie (ABBV) closed at $171.63, indicating a -1% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=0559089892f0445edf2ede60b40d3f0dfbe4cce9e6181ef1753fdd64d2e3ff11"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors despite losses on the day",
    "summary": "AbbVie Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=fed4dc696726cefc26c92305017960790d917b9f58099fc1aaf884fbca93b637",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734366840,
      "headline": "AbbVie Inc. stock outperforms competitors despite losses on the day",
      "id": 132064990,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=fed4dc696726cefc26c92305017960790d917b9f58099fc1aaf884fbca93b637"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Pullback Is A Golden Opportunity For Dividend And Growth Investors",
    "summary": "AbbVie: Pullback Is A Golden Opportunity For Dividend And Growth Investors",
    "url": "https://finnhub.io/api/news?id=c36b762e0116677de3200ce918c2bbe9e56f1fd1e0e4521d2e09de820df29bac",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734362925,
      "headline": "AbbVie: Pullback Is A Golden Opportunity For Dividend And Growth Investors",
      "id": 132015327,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=c36b762e0116677de3200ce918c2bbe9e56f1fd1e0e4521d2e09de820df29bac"
    }
  },
  {
    "ts": null,
    "headline": "ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?",
    "summary": "Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.",
    "url": "https://finnhub.io/api/news?id=ff30c25f5dfdc7d4a8992f5fa1c5a3655dc6370b42853d8fc3aca0ae8bb7395d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734362220,
      "headline": "ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?",
      "id": 132013846,
      "image": "https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.",
      "url": "https://finnhub.io/api/news?id=ff30c25f5dfdc7d4a8992f5fa1c5a3655dc6370b42853d8fc3aca0ae8bb7395d"
    }
  },
  {
    "ts": null,
    "headline": "ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline",
    "summary": "AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.",
    "url": "https://finnhub.io/api/news?id=045f2d4aa1579311e30810a6dc1df9336ed5a49294730d0319006a0eaac2d5ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734360120,
      "headline": "ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline",
      "id": 132013847,
      "image": "https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.",
      "url": "https://finnhub.io/api/news?id=045f2d4aa1579311e30810a6dc1df9336ed5a49294730d0319006a0eaac2d5ca"
    }
  },
  {
    "ts": null,
    "headline": "EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease",
    "summary": "The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.",
    "url": "https://finnhub.io/api/news?id=521b4a3c62765effaf186c598570ecb2b51c468ba4416fff3cee3a4eba952d87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734351780,
      "headline": "EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease",
      "id": 132011828,
      "image": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.",
      "url": "https://finnhub.io/api/news?id=521b4a3c62765effaf186c598570ecb2b51c468ba4416fff3cee3a4eba952d87"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline",
    "summary": "NORTH CHICAGO, MADISON - AbbVie and Nimble Therapeutics today announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R...",
    "url": "https://finnhub.io/api/news?id=63bad3c3e03a6ce8f8aa79982ea7ce5d478ffcc811330069927766f7e1cf0a58",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734347128,
      "headline": "AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline",
      "id": 132012095,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NORTH CHICAGO, MADISON - AbbVie and Nimble Therapeutics today announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R...",
      "url": "https://finnhub.io/api/news?id=63bad3c3e03a6ce8f8aa79982ea7ce5d478ffcc811330069927766f7e1cf0a58"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to acquire Nimble Therapeutics for $200m",
    "summary": "The acquisition includes Nimble's investigational candidate, an oral peptide IL23R inhibitor to treat psoriasis.",
    "url": "https://finnhub.io/api/news?id=68dc60f1cf4809b6c633ffb8263f6e52b7210e6998a3736ca5d509924a43fee7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734339777,
      "headline": "AbbVie to acquire Nimble Therapeutics for $200m",
      "id": 132010823,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/Pharma-1-AbbViee.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The acquisition includes Nimble's investigational candidate, an oral peptide IL23R inhibitor to treat psoriasis.",
      "url": "https://finnhub.io/api/news?id=68dc60f1cf4809b6c633ffb8263f6e52b7210e6998a3736ca5d509924a43fee7"
    }
  },
  {
    "ts": null,
    "headline": "3 closely watched drugs that failed in the clinic",
    "summary": "How recent setbacks and scattered successes could impact various sectors of the industry.",
    "url": "https://finnhub.io/api/news?id=0d09e2331e3594062f5821ccb701a592d2a5ad90c6dc9d784aa564b742ec2efa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734336000,
      "headline": "3 closely watched drugs that failed in the clinic",
      "id": 132013852,
      "image": "https://imgproxy.divecdn.com/QK-fDjBMqdcB6OZK5SjlPeGcEtb6TOnWOgzxmxlXosM/g:nowe:0:2498/c:3839:2169/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS8zMTI0NDMuanBlZw==.webp",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "How recent setbacks and scattered successes could impact various sectors of the industry.",
      "url": "https://finnhub.io/api/news?id=0d09e2331e3594062f5821ccb701a592d2a5ad90c6dc9d784aa564b742ec2efa"
    }
  }
]